WILMINGTON, Mass.--(BUSINESS WIRE)--Kapa Biosystems, Inc. today announced an expanded partnership with Roche NimbleGen to include new, optimized, RNA sample-preparation methods for targeted RNA next-generation sequencing (NGS) applications. Kapa Biosystems will custom manufacture versions of its KAPA Stranded RNA-Seq Kits for Roche NimbleGen to distribute with its recently launched SeqCap RNA Target Enrichment System.
The new offering combines KAPA Stranded RNA-Seq Kits with Roche NimbleGen’s SeqCap RNA Target Enrichment System for complete workflow coverage prior to sequencing. This validated protocol provides customers with a high-resolution view of the transcriptome and the ability to work with a wide range of RNA input, starting as low as 10 ng. Compared to other workflows, this offering provides precise measurement of strand orientation (>99%), uniform coverage, and high-confidence mapping of alternate transcripts. It is also optimized for the improved coverage of GC-rich and low-abundance transcripts. The Roche NimbleGen SeqCap RNA System can be used to evaluate different populations of RNA, including total RNA and non-coding RNA.
“Roche NimbleGen is focused on offering complete, streamlined workflow solutions from sample preparation to target enrichment for a convenient customer experience,” said Rebecca Selzer, President, Roche NimbleGen. “With the SeqCap RNA Target Enrichment System and the KAPA Stranded RNA-Seq Kits, we have combined two proven, industry-leading technology platforms for researchers to study the transcriptome with the sensitivity their experiments require.”
“Over the past year, we have worked together with the team at Roche NimbleGen to provide optimized target-enrichment solutions for DNA analysis,” said John Foskett, Co-Founder and Chief Technology Officer of Kapa Biosystems. “We are now building on the success of this partnership by providing best-in-class products for RNA targeted-sequencing applications, enabling researchers to explore the transcriptome in greater resolution.”
Terms and financials of the partnership were not disclosed.
About Kapa Biosystems
Kapa Biosystems is a life science reagents supplier that employs proprietary, directed-evolution technologies to optimize enzymes for PCR, real-time PCR, next-generation sequencing, and molecular diagnostic applications. Kapa Biosystems offers a portfolio of best-in-class products containing novel enzymes that confer significant performance advantages when compared to traditional wild-type enzymes. The company is based in Wilmington, Massachusetts with a research, development, and manufacturing facility in Cape Town, South Africa. For more information, please visit www.kapabiosystems.com.
NIMBLEGEN and SEQCAP are trademarks of Roche.
KAPA is a trademark of Kapa Biosystems. All other product names and trademarks are the property of their respective owners.
Kapa Biosystems’ products are for Research Use Only; not for use in diagnostic procedures.
